{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T12:46:59Z","timestamp":1793191619622,"version":"4.5.0"},"reference-count":44,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,10,1]],"date-time":"2021-10-01T00:00:00Z","timestamp":1633046400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","seizure-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seizure"],"published-print":{"date-parts":[[2021,10]]},"DOI":"10.1016\/j.seizure.2021.06.020","type":"journal-article","created":{"date-parts":[[2021,6,29]],"date-time":"2021-06-29T04:26:40Z","timestamp":1624940800000},"page":"316-324","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"special_numbering":"C","title":["Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison"],"prefix":"10.1016","volume":"91","author":[{"given":"Nagita","family":"Devi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Priyanka","family":"Madaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mir Mahmood","family":"Asrar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jitendra Kumar","family":"Sahu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dipika","family":"Bansal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.seizure.2021.06.020_bib0001","first-page":"e5006","article-title":"Dravet syndrome: an overview","volume":"11","author":"Anwar","year":"2019","journal-title":"Cureus"},{"issue":"2","key":"10.1016\/j.seizure.2021.06.020_bib0002","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/j.1528-1167.2011.02997.x","article-title":"The genetics of Dravet syndrome","volume":"52","author":"Marini","year":"2011","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2021.06.020_bib0003","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1086\/320609","article-title":"De novo mutations in the sodium-channel gene SCN1A cause severe myoclonic epilepsy of infancy","volume":"68","author":"Claes","year":"2001","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.seizure.2021.06.020_bib0004","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.cophys.2017.12.007","article-title":"Dravet syndrome: a sodium channel interneuronopathy","volume":"2","author":"Catterall","year":"2018","journal-title":"Curr Opin Physiol"},{"issue":"1","key":"10.1016\/j.seizure.2021.06.020_bib0005","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1001\/archneurol.2008.559","article-title":"Translational research in epilepsy genetics: sodium channels in man to interneuronopathy in mouse","volume":"66","author":"Mullen","year":"2009","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2021.06.020_bib0006","first-page":"255","article-title":"Treatment of seizures associated with lennox-gastaut and dravet syndromes: a focus on cannabidiol oral solution","volume":"44","author":"Lazaridis","year":"2019","journal-title":"P & T: a Peer-Rev J Formulary Manag"},{"issue":"2","key":"10.1016\/j.seizure.2021.06.020_bib0007","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1111\/j.1528-1167.2011.03001.x","article-title":"Dravet syndrome: the long-term outcome","volume":"52","author":"Genton","year":"2011","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.06.020_bib0008","first-page":"2090","volume":"3","author":"Wahab","year":"2010"},{"issue":"4","key":"10.1016\/j.seizure.2021.06.020_bib0009","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40263-018-0511-y","article-title":"Treatment strategies for dravet syndrome","volume":"32","author":"Knupp","year":"2018","journal-title":"CNS Drugs"},{"issue":"9","key":"10.1016\/j.seizure.2021.06.020_bib0010","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40263-019-00666-8","article-title":"Recent advances in the drug treatment of dravet syndrome","volume":"33","author":"Wirrell","year":"2019","journal-title":"CNS Drugs"},{"issue":"16","key":"10.1016\/j.seizure.2021.06.020_bib0011","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1007\/s40265-019-01204-y","article-title":"Stiripentol: a review in dravet syndrome","volume":"79","author":"Frampton","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.seizure.2021.06.020_bib0012","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.yebeh.2018.08.021","article-title":"Individualized treatment approaches: fenfluramine, a novel antiepileptic medication for the treatment of seizures in Dravet syndrome","volume":"91","author":"Polster","year":"2019","journal-title":"Epilepsy Behavior: E&B"},{"issue":"S1","key":"10.1016\/j.seizure.2021.06.020_bib0013","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1684\/epd.2020.1135","article-title":"The proposed mechanisms of action of CBD in epilepsy","volume":"22","author":"Gray","year":"2020","journal-title":"Epileptic Disord"},{"key":"10.1016\/j.seizure.2021.06.020_bib0014","doi-asserted-by":"crossref","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"10.1016\/j.seizure.2021.06.020_bib0015","unstructured":"Higgins JPT SJ, Page M.J., Sterne JAC on behalf of the RoB2 Development Group. A revised tool to assess risk of bias in randomized trials (RoB 2) 2020 [Available from: https:\/\/www.riskofbias.info\/welcome\/rob-2-0-tool\/current-version-of-rob-2."},{"issue":"3","key":"10.1016\/j.seizure.2021.06.020_bib0016","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1001\/jamaneurol.2019.4113","article-title":"Fenfluramine for treatment-resistant seizures in patients with dravet syndrome receiving stiripentol-inclusive regimens: a randomized clinical trial","volume":"77","author":"Nabbout","year":"2019","journal-title":"JAMA Neurol"},{"issue":"5","key":"10.1016\/j.seizure.2021.06.020_bib0017","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaneurol.2020.0073","article-title":"Dose-ranging effect of adjunctive oral cannabidiol vs placebo on convulsive seizure frequency in dravet syndrome: a randomized clinical trial","volume":"77","author":"Miller","year":"2020","journal-title":"JAMA Neurol"},{"issue":"10216","key":"10.1016\/j.seizure.2021.06.020_bib0018","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1016\/S0140-6736(19)32500-0","article-title":"Fenfluramine hydrochloride for the treatment of seizures in Dravet syndrome: a randomised, double-blind, placebo-controlled trial","volume":"394","author":"Lagae","year":"2019","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.seizure.2021.06.020_bib0019","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1056\/NEJMc1708349","article-title":"Trial of cannabidiol for drug-resistant seizures in the dravet syndrome","volume":"377","author":"Devinsky","year":"2017","journal-title":"New Eng J Med"},{"key":"10.1016\/j.seizure.2021.06.020_bib0020","first-page":"1638","volume":"356","author":"Chiron","year":"2000"},{"key":"10.1016\/j.seizure.2021.06.020_bib0021","series-title":"Cochrane handbook for systematic reviews of interventions","article-title":"Measures of relative effect: the risk ratio and odds ratio","author":"Deeks","year":"2011"},{"issue":"2","key":"10.1016\/j.seizure.2021.06.020_bib0022","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s13311-020-00835-4","article-title":"From genetic testing to precision medicine in epilepsy","volume":"17","author":"Striano","year":"2020","journal-title":"Neurotherapeutics"},{"issue":"8","key":"10.1016\/j.seizure.2021.06.020_bib0023","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/epi.13057","article-title":"Summary of recommendations for the management of infantile seizures: task Force Report for the ILAE Commission of Pediatrics","volume":"56","author":"Wilmshurst","year":"2015","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.seizure.2021.06.020_bib0024","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1053\/seiz.2000.0466","article-title":"Topiramate in the treatment of severe myoclonic epilepsy in infancy","volume":"9","author":"Nieto-Barrera","year":"2000","journal-title":"Seizure"},{"issue":"6","key":"10.1016\/j.seizure.2021.06.020_bib0025","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1055\/s-2007-964867","article-title":"Topiramate in the treatment of highly refractory patients with Dravet syndrome","volume":"37","author":"Kr\u00f6ll-Seger","year":"2006","journal-title":"Neuropediatrics"},{"issue":"11","key":"10.1016\/j.seizure.2021.06.020_bib0026","doi-asserted-by":"crossref","first-page":"2362","DOI":"10.1111\/j.1528-1167.2009.02179.x","article-title":"Stiripentol open study in Japanese patients with Dravet syndrome","volume":"50","author":"Inoue","year":"2009","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.06.020_bib0027","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.eplepsyres.2014.10.014","article-title":"Efficacy and tolerability of the ketogenic diet in Dravet syndrome - Comparison with various standard antiepileptic drug regimen","volume":"109","author":"Dressler","year":"2015","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2021.06.020_bib0028","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/S0920-1211(02)00010-4","article-title":"Topiramate as add-on drug in severe myoclonic epilepsy in infancy: an Italian multicenter open trial","volume":"49","author":"Coppola","year":"2002","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.seizure.2021.06.020_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.eplepsyres.2020.106535","article-title":"Long-term safety and effectiveness of stiripentol in patients with Dravet syndrome: interim report of a post-marketing surveillance study in Japan","volume":"170","author":"Yamada","year":"2021","journal-title":"Epilepsy Res"},{"issue":"6","key":"10.1016\/j.seizure.2021.06.020_bib0030","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/dmcn.13704","article-title":"Stiripentol efficacy and safety in Dravet syndrome: a 12-year observational study","volume":"60","author":"Myers","year":"2018","journal-title":"Develop Med Child Neurol"},{"key":"10.1016\/j.seizure.2021.06.020_bib0031","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.yebeh.2014.12.028","article-title":"The European patient with Dravet syndrome: results from a parent-reported survey on antiepileptic drug use in the European population with Dravet syndrome","volume":"44","author":"Aras","year":"2015","journal-title":"Epilepsy Behav"},{"issue":"11","key":"10.1016\/j.seizure.2021.06.020_bib0032","doi-asserted-by":"crossref","first-page":"2396","DOI":"10.1111\/epi.16722","article-title":"Fenfluramine HCl (Fintepla(\u00ae)) provides long-term clinically meaningful reduction in seizure frequency: analysis of an ongoing open-label extension study","volume":"61","author":"Sullivan","year":"2020","journal-title":"Epilepsia"},{"issue":"2","key":"10.1016\/j.seizure.2021.06.020_bib0033","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1111\/epi.14628","article-title":"Long-term cannabidiol treatment in patients with Dravet syndrome: an open-label extension trial","volume":"60","author":"Devinsky","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.06.020_bib0034","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.eplepsyres.2015.03.012","article-title":"Long-term safety and efficacy of stiripentol for the treatment of Dravet syndrome: a multicenter, open-label study in Japan","volume":"113","author":"Inoue","year":"2015","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2021.06.020_bib0035","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5-HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald","year":"2000","journal-title":"Mol Pharmacol"},{"issue":"11","key":"10.1016\/j.seizure.2021.06.020_bib0036","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1111\/epi.16638","article-title":"Cardiovascular safety of fenfluramine in the treatment of Dravet syndrome: analysis of an ongoing long-term open-label safety extension study","volume":"61","author":"Lai","year":"2020","journal-title":"Epilepsia"},{"issue":"7","key":"10.1016\/j.seizure.2021.06.020_bib0037","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1111\/j.1528-1167.2012.03495.x","article-title":"Successful use of fenfluramine as an add-on treatment for Dravet syndrome","volume":"53","author":"Ceulemans","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.seizure.2021.06.020_bib0038","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.eplepsyres.2019.03.015","article-title":"Long-term safety and efficacy of cannabidiol in children and adults with treatment resistant Lennox-Gastaut syndrome or Dravet syndrome: expanded access program results","volume":"154","author":"Laux","year":"2019","journal-title":"Epilepsy Res"},{"issue":"1","key":"10.1016\/j.seizure.2021.06.020_bib0039","doi-asserted-by":"crossref","first-page":"11","DOI":"10.5414\/CP203276","article-title":"A phase I, randomized, open-label, single-dose, 3-period crossover study to evaluate the drug-drug interaction between ZX008 (fenfluramine HCl oral solution) and a regimen of stiripentol, clobazam, and valproate in healthy subjects","volume":"57","author":"Boyd","year":"2019","journal-title":"Int J Clin Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.seizure.2021.06.020_bib0040","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1002\/cpdd.665","article-title":"A phase 1, open-label, pharmacokinetic trial to investigate possible drug-drug interactions between clobazam, stiripentol, or valproate and cannabidiol in healthy subjects","volume":"8","author":"Morrison","year":"2019","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"3","key":"10.1016\/j.seizure.2021.06.020_bib0041","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1017\/cjn.2016.243","article-title":"Dravet Syndrome: diagnosis and Long-Term Course","volume":"43","author":"Connolly","year":"2016","journal-title":"Can J Neurol Sci"},{"issue":"4","key":"10.1016\/j.seizure.2021.06.020_bib0042","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1111\/epi.12532","article-title":"Long-term course of Dravet syndrome: a study from an epilepsy center in Japan","volume":"55","author":"Takayama","year":"2014","journal-title":"Epilepsia"},{"issue":"6","key":"10.1016\/j.seizure.2021.06.020_bib0043","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1111\/j.1528-1167.2009.02466.x","article-title":"A long-term follow-up study of Dravet syndrome up to adulthood","volume":"51","author":"Akiyama","year":"2010","journal-title":"Epilepsia"},{"issue":"03","key":"10.1016\/j.seizure.2021.06.020_bib0044","doi-asserted-by":"crossref","first-page":"094","DOI":"10.1055\/s-0040-1714065","article-title":"Ethical, social, and economic challenges in managing a child with dravet syndrome in a developing country","volume":"9","author":"Gulati","year":"2020","journal-title":"J Pediatr Epilepsy"}],"container-title":["Seizure"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002041?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1059131121002041?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T02:02:11Z","timestamp":1761012131000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1059131121002041"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10]]},"references-count":44,"alternative-id":["S1059131121002041"],"URL":"https:\/\/doi.org\/10.1016\/j.seizure.2021.06.020","relation":{},"ISSN":["1059-1311"],"issn-type":[{"value":"1059-1311","type":"print"}],"subject":[],"published":{"date-parts":[[2021,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative short-term efficacy and safety of add-on anti-seizure medications in Dravet syndrome: An indirect treatment comparison","name":"articletitle","label":"Article Title"},{"value":"Seizure","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.seizure.2021.06.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 British Epilepsy Association. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}